Key Developments For Solta Medical, Inc
Solta Medical, Inc (SLTM.O) (Consolidated Issue listed on NASDAQ Global Market)
Solta Medical, Inc. Revises FY 2009 Revenue Guidance; Reaffirms FY 2009 EBITDA Guidance
Solta Medical, Inc. announced that it has updated fiscal 2009 guidance and now expects revenue in the range of $95 million to $98 million and to generate positive EBITDA. According to Reuters Estimates, analysts are expecting the Company to report revenue of $96 million for fiscal 2009.
Solta Medical, Inc. Announces FDA 510(k) Clearance Of New Fraxel re:store Dual Laser System
Solta Medical, Inc. announced that it it has received FDA 510(k) clearance for the new Fraxel re:store Dual laser system. The new Fraxel re:store Dual system is optimized for both on face and large body areas to address clearance of pigmentation and other superficial skin conditions all in a single treatment.
Solta Medical, Inc. Issues Q3 2009 Revenue Guidance Below Analysts' Estimates; Reaffirms FY 2009 EBITDA Guidance
Solta Medical, Inc. announced that for the third quarter of 2009, the Company expects to report revenue between $17.0 million to $19.0 million. The Company further announced that for fiscal 2009, it expects to generate positive EBITDA. According to Reuters Estimates, analysts are expecting the Company to report revenue of $26.9 million for the third quarter of 2009.
Solta Medical, Inc. Launches New Fraxel re:store Dual Laser System
Solta Medical, Inc. announced the launch of its new Fraxel re:store Dual system, providing superior results for large body areas during a single treatment.
Solta Medical, Inc. Announces Launch Of Its New Thermage CPT System
Solta Medical, Inc. announced the launch of its new Thermage CPT system. The Thermage CPT system incorporates Comfort Pulse Technology in every aspect of the system including a new ergonomic vibrating hand piece and scientifically advanced Face Tip 3.0 and Body Tip 16.0 treatment tips.
